Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImpedimedASX:IPD Cash-to-Debt is 0.87 as of Dec. 2025, which is 98% below its 10-year median of 36.56. The stock has 6 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Impedimed ranks worse than 61.7% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Impedimed's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.87.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Impedimedcouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Impedimed's Cash-to-Debt or its related term are showing as below:
ASX:IPD'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.87 Med: 36.56 Max: No Debt
Current: 0.87
During the past 13 years, Impedimed's highest Cash to Debt Ratio was No Debt. The lowest was 0.87. And the median was 36.56.
ASX:IPD's Cash-to-Debt is ranked worse than 61.7% of 846
companies
in the Medical Devices & Instruments industry
Industry Median: 1.68
vs ASX:IPD: 0.87
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Impedimed Cash-to-Debt Related Terms
Impedimed Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Impedimed's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, Impedimed's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Impedimed Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Impedimed's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Impedimed's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Impedimed (ASX:IPD) has a Cash-to-Debt of 0.87 as of Dec. 2025. This is 98% below median its historical median of 36.56. Over the past decade, Impedimed's Cash-to-Debt has ranged from 0.87 to 10,000.00. According to the industry distribution chart, Impedimed ranks #522 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 61.7%.
Is Impedimed's Cash-to-Debt too high?
Impedimed's current Cash-to-Debt of 0.87 is 98% below median its 10-year median of 36.56. Over the past 10 years, this metric has ranged from a low of 0.87 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.68. Impedimed's value of 0.87 is 48.2% below this industry median. Based on the distribution chart, Impedimed ranks #522 out of 846 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Impedimed's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Impedimed ranks #522 out of 846 companies for Cash-to-Debt. This places Impedimed in the lower half of its industry. The industry median Cash-to-Debt is 1.68. Impedimed's value of 0.87 is 48.2% below this benchmark. Historically, Impedimed's own Cash-to-Debt has ranged from 0.87 to 10,000.00 over the past decade. While the company's 10-year median is 36.56 vs. the industry median of 1.68, Impedimed has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.68, based on 846 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Impedimed's current Cash-to-Debt of 0.87 is 48.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Impedimed's current Cash-to-Debt is 0.87, which is 98% below median its own 10-year median of 36.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impedimed stock overvalued right now?
Impedimed (ASX:IPD) has a current Cash-to-Debt of 0.87. The current Cash-to-Debt is 0.87, which is 98% below median its 10-year median of 36.56 and 48.2% below the Medical Devices & Instruments industry median of 1.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Impedimed (ASX:IPD), the current Cash-to-Debt is 0.87 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IPD has been successfully added to your 
